Researchers at Lund University have unexpectedly discovered that an old cancer drug can be used to prevent rejection of transplanted tissue.
The researchers now have high hopes that their discovery could lead to new treatments for both transplant patients and patients with autoimmune diseases.
The researchers behind the study, which has been published in the scientific journal PLOS ONE, work at the Rausing Laboratory, Lund University, where they have conducted research on brain tumours over many years.
“Our group were studying the effects of the old tumour drug Zebularine, developed in the USA in the 1960s, and by chance we discovered that it had completely unexpected effects on the immune system”, says Leif Salford, Senior Professor of Neurosurgery.
“It turned out that Zebularine has the ability to subdue the reaction of the body’s immune system. This could be important in situations where tissue or organs are transplanted. We also think it could be used to curb the body’s attacks on its own tissue in autoimmune diseases, for instance type 1 diabetes or rheumatoid arthritis”, says Dr Nittby.
In studies on animals, the researchers used rats that were made diabetic. The researchers transplanted the islets of Langerhans – cell groups in the pancreas producing insulin – from healthy rats from another kind of rat into those with diabetes. The diabetic rats were divided into two groups; one group were treated with Zebularine and the other, the control group, did not receive any treatment. The diabetic rats that were treated with Zebularine survived for a significantly longer period than the untreated rats.
“It is very interesting that we only treated them with Zebularine for two weeks, but the effects of the treatment could be observed throughout the 90-day follow-up period.
“The findings are very exciting and are a sign that the immune system was not just generally suppressed, but that the treatment was more targeted. Neither did we see any signs of side-effects”, said Dr Nittby.
The researchers are now working intensively to further refine the treatment. The next step is to teach certain cells in the immune system – the dendritic cells – to accept certain specific proteins using the Zebularine treatment.
This would mean that the treatment could be targeted even more.
“If we succeed with that, we believe it could be of clinical significance both to prevent rejection of transplanted organs and to stop the body attacking its own tissue in autoimmune diseases.
The Latest Bing News on:
- Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemiaon June 25, 2020 at 2:29 am
The FDA-approved DNA hypomethylating agents (DHAs) like 5-azacytidine (5AC) and decitabine (DAC) demonstrate efficacy in the treatment of hematologic malignancies. Despite previous reports that showed ...
- Epigenetics of Estrogen Receptor-Negative Primary Breast Canceron June 18, 2020 at 5:00 pm
Expert Rev Mol Diagn. 2012;12(4):371-382. Table 1. Epigenetic elements that regulate ERα expression in breast cancer. Epigenetic element Molecular expression in ER-negative breast cancer Effect ...
- Epigenetic Biomarkers in Urothelial Bladder Canceron June 17, 2020 at 5:00 pm
Epigenetic treatment of bladder cancer is now ongoing in several medical centers. There are several additional chromatin modifications other than deacetylation, such as the methylation of key ...
- DNA methylome and transcriptome landscapes revealed differential characteristics of dioecious flowers in papayaon May 31, 2020 at 5:00 pm
Chemical hypomethylation in Silene latifolia and Diospyros kaki with the application of 5-azacytide or zebularine induced a striking sex reversion 4,6. In melon, methylation alteration of sex ...
The Latest Google Headlines on:
The Latest Bing News on:
Preventing rejection of transplanted tissue
- Researchers seeking to understand the connection between SARS-CoV-2 and a deadly immune system malfunctionon June 29, 2020 at 9:23 am
It describes a furious gale-force swarm of molecules unleashed by the body's immune system that causes extreme inflammation, tissue damage, even death. Cytokines—from the Greek cyto for cells and ...
- TFF Pharmaceuticals Announces First Human Dosing With Tacrolimus Inhalation Powder and Topline Data for Voriconazole Inhalation Powderon June 29, 2020 at 8:42 am
TFF Pharmaceuticals announces first human posing with Tacrolimus Inhalation Powder and topline Phase I data for Voriconazole Inhalation Powder.
- TFF Pharmaceuticals Receives Orphan Drug Designation for Tacrolimus Inhalation Powderon June 18, 2020 at 6:00 am
TFF Pharmaceuticals receives orphan drug designation for Tacrolimus Inhalation Powder for prophylaxis of lung allograft rejection.
- C-Path's Transplant Therapeutics Consortium Letter of Intent accepted by FDAon June 17, 2020 at 7:42 am
Critical Path Institute (C-Path) announced today that its Transplant Therapeutics Consortium (TTC) has received a positive response to its Letter of Intent (LOI) from the US Food and Drug ...
- Immune system discovery paves way to lengthen organ transplant survival: Studyon June 14, 2020 at 5:00 pm
The missing link in the field of organ transplantation is a specific way to prevent rejection ... once exposed to foreign tissue, could remember and initiate an immune response if exposed to ...
- Chronic Rejection: A Significant Role for Th17-mediated Autoimmune Responses to Self-antigenson June 10, 2020 at 5:00 pm
Donor-specific alloimmune responses both pretransplant and de novodevelopment post-transplant are important risk factors for chronic rejection. Autoimmune responses to tissue-restricted self ...
- Donor bone-marrow CXCR4+ Foxp3+ T-regulatory cells are essential for costimulation blockade-induced long-term survival of murine limb transplantson June 8, 2020 at 5:00 pm
Vascularized composite allotransplantation (VCA) allows tissue replacement ... long-bone removal or pre-transplant donor irradiation prevented long-term engraftment. Rejection also occurred ...
- Immune Recognition and Rejection of Allogeneic Skin Graftson June 1, 2020 at 5:00 pm
However, allogeneic skin grafts are invariably rejected in an acute fashion. While current immunosuppressive treatments are effective in preventing early rejection of organ transplants ...
- Prophylaxis of Organ Rejection Marketon May 31, 2020 at 5:00 pm
The Prophylaxis of Organ Rejection Market analysis report enumerates information about the key companies based on their market position in the present scenario along with data related to the ...
- Blocking molecule could prevent "slow burn" organ transplant rejectionon May 26, 2020 at 5:00 pm
Organ transplants are often necessary ... could reduce the immune system’s overzealousness and hopefully prevent organ rejection. The mechanism behind this slower form of rejection involves ...